For the year ending 2025-12-31, AIDX had -$758,022 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -3,738,821 |
| Depreciation and amortization | 63,257 |
| Stock based compensation | 516,180 |
| Amortization of license fees | 22,500 |
| Amortization of right-of-use assets, net of liabilities | 7,781 |
| Amortization of debt discount | 115,184 |
| Change in fair value of derivative liability | -7,737 |
| Loss on issuance of convertible note | -280,764 |
| Accounts receivable | 64,682 |
| Inventory | 69,052 |
| Prepaid expenses and other assets | -77,705 |
| Accounts payable | 496,242 |
| Accrued liabilities | 419,263 |
| Interest payable | 41,023 |
| Deferred revenue | -63,765 |
| Net cash used in operating activities | -1,919,720 |
| Proceeds from issuance of convertible notes payable | 988,472 |
| Proceeds from issuance of series d preferred stock | 192,338 |
| Proceeds from issuance of pre-delivery shares | 4,750 |
| Deferred offering costs | 23,862 |
| Net cash provided by financing activities | 1,161,698 |
| Decrease in cash and cash equivalents | -758,022 |
| Cash and cash equivalents, beginning of year | 1,784,009 |
| Cash and cash equivalents, end of year | 1,025,987 |
20 20 Biolabs, Inc. (AIDX)
20 20 Biolabs, Inc. (AIDX)